# DSIP vs Melatonin for Sleep: Differences, Research & Which to Consider **By TelosRX Clinical Team** · 2026-08-03 **DSIP and melatonin both influence sleep, but they work through entirely different mechanisms and represent different intervention categories. Here is what the research shows, subject to medical approval by a licensed provider at [TelosRX](https://telosrx.com).** Choosing between them requires understanding what each actually does — and which sleep problem each is best positioned to address. This comparison covers mechanism, evidence base, safety, access, and cost so you can have an informed conversation with a licensed provider. ## What Is Melatonin? Melatonin is a hormone produced by the pineal gland in response to darkness. It signals to the brain that nighttime has arrived, helping regulate the circadian rhythm — the roughly 24-hour internal clock governing sleep-wake cycles, body temperature, and hormonal release patterns. As an over-the-counter supplement, melatonin is available at any pharmacy in doses ranging from 0.5 mg to 10 mg or more. Research consistently shows that low-dose melatonin (0.5–3 mg) is effective for shifting the _timing_ of sleep — making it particularly useful for jet lag, shift work disorder, and delayed sleep phase. Melatonin does not directly produce sedation; it resets the clock. Its effects are strongest when taken approximately 30–60 minutes before the desired new bedtime. ## What Is DSIP? Delta sleep-inducing peptide (DSIP) is a nine-amino-acid neuropeptide first isolated in 1974 from rabbit brain perfusate during slow-wave sleep. Researchers observed that infusing DSIP into other animals increased delta (slow-wave) activity on EEG recordings — which gave the peptide its name. DSIP is thought to act through GABAergic signaling, NMDA receptor modulation, and endogenous opioid systems — a more complex and less fully characterized mechanism than melatonin's receptor-specific action. Some research has also examined DSIP's effects on cortisol and the hypothalamic-pituitary-adrenal (HPA) axis. For a deeper look at the existing DSIP literature, see our overview of [what research shows about DSIP, sleep, and stress](https://www.telosrx.com/blogs/peptides/dsip-what-research-shows-sleep-stress). Compounded DSIP is not FDA-approved. It is prepared by licensed compounding pharmacies under federal compounding regulations and requires a prescription from a licensed provider. ## Side-by-Side Comparison Feature DSIP Melatonin Mechanism GABAergic / NMDA / HPA modulation; promotes delta (slow-wave) sleep MT1/MT2 receptor agonism; signals circadian nighttime FDA Status Not FDA-approved; compounded under federal regulations GRAS supplement; OTC — not subject to drug approval Primary Use Deep/slow-wave sleep quality; stress-driven sleep disruption Circadian phase-shifting; jet lag; sleep onset timing Typical Dose 0.25–0.5 mg subcutaneous (research-based; provider-determined) 0.5–5 mg oral (OTC; lower doses often more effective) Key Side Effects Limited human data; mild sedation in studies Morning grogginess (higher doses); vivid dreams Access Prescription through licensed compounding pharmacy OTC at any pharmacy without prescription ## How Their Mechanisms Differ Melatonin's mechanism is among the best-characterized in sleep science. It binds to MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) — the brain's master circadian clock. MT1 activation suppresses SCN neuronal firing, promoting sleep onset. MT2 activation is more involved in circadian phase-shifting: essentially moving the body's internal clock to a new time zone. DSIP's mechanism is less precisely mapped. Early work showed that intravenous or intracerebroventricular infusion increased slow-wave sleep time in animal models. More recent interest has focused on DSIP's effects on the HPA axis, where it appears to modulate stress-induced cortisol activity — suggesting a role in sleep quality that extends beyond sedation into stress biology. The practical distinction: melatonin addresses _when_ you sleep, while DSIP research focuses on _how deeply_ you sleep and whether stress is disrupting architecture. These address different problems and are not interchangeable. ## Reviewing the Clinical Evidence Melatonin has one of the most robust evidence bases in sleep medicine. Meta-analyses of randomized controlled trials confirm its efficacy for jet lag, shift work disorder, and delayed sleep phase, with consistent positive effects on sleep onset latency and total sleep time. Doses as low as 0.3 mg have demonstrated measurable circadian phase-shifting effects. DSIP's human evidence base is narrower and older — primary human studies date primarily to the 1980s and 1990s, often with small sample sizes and variable administration routes. Some trials showed improvements in total sleep time and subjective sleep quality; others showed mixed results. A complicating factor: DSIP crosses the blood-brain barrier poorly when administered peripherally, which complicates direct translation of intracerebroventricular animal findings to subcutaneous human dosing. This does not make DSIP without research merit — it means the evidence framework requires a different interpretive lens than for melatonin, which has been studied in thousands of participants over decades. ## Which Sleep Problems Each Addresses Understanding which intervention fits requires identifying the type of sleep problem. Melatonin is best suited for: - Jet lag and rapid time zone transitions - Shift work sleep disorder from circadian misalignment - Delayed sleep phase — chronotypes that want to sleep and wake later than is practical - General difficulty falling asleep when the issue is circadian timing Compounded DSIP may be considered (under licensed provider oversight, as it is not FDA-approved) for: - Poor slow-wave sleep quality when circadian timing is not the primary issue - Sleep disruption in the context of elevated stress or HPA axis dysregulation - Individuals who have addressed circadian timing and lifestyle factors without adequate resolution of sleep depth These categories are not mutually exclusive — sleep disorders frequently have multiple contributing factors. For a broader view of how sleep intersects with longevity biology, see our discussion of [sleep optimization for longevity](https://www.telosrx.com/blogs/hormone-longevity/sleep-optimization-longevity-answered). ## Safety and Side-Effect Profiles Melatonin's safety profile is well-established through decades of research and widespread use. Short-term use is associated with minimal adverse effects. The most commonly reported are morning grogginess (more common at doses above 3–5 mg), vivid dreams, and mild headache. Long-term safety data broadly support its OTC use, though some researchers have questioned the effects of habitually high doses on endogenous melatonin production over time. DSIP human safety data are more limited by comparison. Studies conducted to date have not identified major adverse events; mild sedation during infusion has been noted in some research participants. Because the human trial database is smaller than melatonin's, the full side-effect profile across diverse populations and doses is less well-characterized. This underscores the importance of licensed provider oversight for compounded peptides — approval is not guaranteed and each case is evaluated individually on clinical merit. ## Cost, Access, and What to Expect Melatonin is inexpensive and universally accessible — typically $5–20 for a month's supply OTC, requiring no prescription, no provider visit, and available in virtually every country. Compounded DSIP requires a prescription from a licensed provider, preparation by a licensed compounding pharmacy, and carries a higher cost that varies by pharmacy, dose, and formulation. At [TelosRX](https://telosrx.com), evaluations are conducted asynchronously by licensed providers — no in-person visit required — but approval is subject to clinical review and is not guaranteed. Compounded DSIP is not FDA-approved. ## Sleep Architecture and the Hormonal Picture Neither DSIP nor melatonin exists in isolation from the broader hormonal environment. Testosterone, growth hormone, and cortisol all follow circadian patterns tightly coupled to sleep architecture. Disrupted slow-wave sleep in particular reduces the amplitude of nighttime growth hormone release and can impair testosterone recovery — both of which matter for long-term metabolic and longevity outcomes. For a detailed look at this relationship, see our analysis of [how sleep and testosterone interact](https://www.telosrx.com/blogs/hormone-longevity/sleep-and-testosterone-hormones-explainer). This interconnection matters for intervention selection: someone with poor slow-wave sleep and low morning testosterone faces a different clinical picture than someone with pure circadian delay and adequate sleep depth. A thorough evaluation considers the full hormonal and sleep architecture picture, not just which intervention is more widely recognized. ## Frequently Asked Questions ### Is DSIP FDA-approved? No. Compounded DSIP is not FDA-approved and is prepared under federal compounding regulations by licensed pharmacies. Melatonin is classified as Generally Recognized as Safe (GRAS) and available OTC, but it is also not FDA-approved as a drug for specific medical indications. ### Can DSIP and melatonin be used together? Because they address different aspects of sleep — timing versus architecture — there is theoretical complementarity. However, combining any interventions requires clinical oversight. A licensed provider would evaluate whether concurrent use is appropriate for an individual's health history and goals. ### How is compounded DSIP administered? Research protocols have used intravenous, intracerebroventricular, and subcutaneous routes. Subcutaneous injection is the form relevant to current compounding practice. Dose and administration frequency are determined by a licensed provider based on individual assessment. ### Does melatonin work for everyone? Melatonin is most effective for circadian timing problems. For sleep difficulty that is primarily architectural — insufficient deep sleep or frequent waking — rather than timing-related, melatonin may have limited impact. Identifying the type of sleep problem determines which intervention is relevant. ### What does the research say about DSIP dosing? Human research has used a range of doses and administration routes. Subcutaneous protocols in current practice typically range from 0.25 to 0.5 mg, though this varies by individual and clinical context. A licensed provider determines appropriate dosing based on current literature and individual factors. ### Do I need a prescription for DSIP? Yes. Compounded DSIP requires a prescription from a licensed provider and is not available OTC. An asynchronous telehealth evaluation can initiate this process without an in-person visit, subject to provider approval. _TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._ Start your private evaluation at [TelosRX](https://telosrx.com). **Tags:** comparison, delta sleep-inducing peptide, DSIP, longevity, melatonin, peptides, sleep, sleep optimization --- > Source: [Telos RX](https://www.telosrx.com/blogs/hormone-longevity/dsip-vs-melatonin-sleep-comparison)